Literature DB >> 28454403

miR-22 promotes apoptosis of osteosarcoma cells via inducing cell cycle arrest.

Pengzhou Gai1, Hongliang Sun1, Guangda Wang1, Qiang Xu1, Xiaojun Qi1, Zuofu Zhang1, Lei Jiang2.   

Abstract

To study the effects of miR-22 on the proliferation and the apoptosis of osteosarcoma MG-63 cell line and to explore the potential molecular mechanism that miR-22 regulates this biological process. Quantitive real-time polymerase chain reaction (RT-qPCR) was performed to explore the miRNA level of miR-22. The MG-63 cell line was infected with miR-22 mimics for establishment of miR-22 overexpression. Non-infected cells were in blank group and cells infected with empty vector were served as negative control (NC group). MTT assay was conducted to measure cell viability. The cell cycle and apoptosis were explored using flow cytometry and the apoptosis-related markers were detected by western blotting. RT-qPCR results revealed that the miR-22 miRNA level in the MG-63 cells was significantly lower than that in osteoblasts (P<0.05). MTT assay showed that the MG-63 cells infected with miR-22 mimics exhibited markedly decreased proliferation ability compared with blank and empty vector (NC) groups. Next, we found that overexpression of miR-22 remarkably increased the apoptosis of the MG-63 cells, evidenced from the flow cytometry results and elevated Bax and reduced Bcl-2. Furthermore, results revealed that percentage of the cells at G0/G1 phase in miR-22 mimic group (66.75±3.67%) was significantly higher than blank (52.9±2.58%) and NC (50.5±2.45%) groups. miR-22 attenuated the proliferation and induced the apoptosis of the MG-63 cells via promoting G0/G1 cell cycle arrest. Thus, miR-22 may have the potential to be a novel therapeutic in treatment of osteosarcoma.

Entities:  

Keywords:  cell apoptosis; cell cycle arrest; cell proliferation; miR-22; osteosarcoma

Year:  2017        PMID: 28454403      PMCID: PMC5403490          DOI: 10.3892/ol.2017.5674

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


Introduction

As a primary tumor of bone, osteosarcoma (OS) is believed to be derived from the malignant mesenchymal stem cells (1,2). The tumor usually develops in the metaphyses of the long bones, such as the proximal humerus, the distal femur, and the proximal tibia (3). Although in the past decades, the neoadjuvant chemotherapy combined with the local control have been applied to ameliorate the outcomes of patients with OS, the rate of 5-year survival rises to approximately 65%, and after metastasis or recurrence the rate is significantly lowered to approximately 30% (4–6). In addition, patients with OS metastasis to some other tissues such as lung mostly decease in about 6–12 months (7). miRNAs, approximately 22–25 nt in length, are a kind of non-coding small RNAs and are crucial mediators on post-transcriptional gene expression (8,9). Mature miRNAs regulate the gene expression through binding 3′-UTR of their target genes, resulting in either decreased protein translation or miRNA degradation (10,11). Abnormal level of miRNAs was found to contribute to various malignant tumors, including OS (12–14). Zhu et al found that miR-29b can exert its tumor-suppressive function in OS via targeting CDK6 (15). In another study, miR-140 was showed to be associated with the chemoresistance by reducing cell proliferation through G1/G2 phase arrest mediated partly through the suppression of HDAC4 (16). Recent studies have demonstrated the important role of miR-22 in the occurrence and development of OS. Xin et al suggested that miR-22 could significantly attenuate tumor growth and metastasis by targeting ATP citrate lyase (17). However, how miR-22 exerts its antitumor effects remains unclear. The aim of our present study was to explore the miR-22 effects on the proliferation and the apoptosis in the osteosarcoma MG-63 cell line, and to investigate its potential underlying mechanism.

Materials and methods

Cell culture

The human MG-63 cell line was purchased from Shanghai Institute of Cell Biology (Shanghai, China). Cells were cultivated in the DMEM coupled with 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100 itg/ml streptomycin, and 2 mM glutamine (BioSharp, Hefei, China).

Cell transfection

miR-22 mimic and the negative control were supplied by GenePharma (Shanghai, China). For transfection, the MG-63 cell line was planted in a 12-well plate at a 5×104/ml density and were transfected with 100 nM of miR-22 mimic or NC using Lipofectamine 3000 (Life Technologies, Gaithersburg, MD, USA) and then incubated for 6 h. Following transfection, medium were changed to 2% FBS-DMEM without antibiotics.

Real-time qPCR

Isolation of the total cellular RNA was performed following the manufacturers instructions of miRNeasy Mini kit (Qiagen, Hilden, Germany) and the levels of miRNA were quantified using the miRNA assay (TaqMan; Applied Biosystems). The RT-qPCR experiment was carried on a real-time quantified PCR system (ABI StepOne and StepOnePlus; Applied Biosystems) with LightCycler 480 (Roche). The miRNA levels were detected from the relative threshold cycle, which were determined using the method of arithmetic formulas 2−ΔΔcp normalizated to level of the U6 small nuclear RNA.

MTT assay

The cells viability was detected following the introduction of the MTT assay. At various time-points after transfection (6, 12, 24 and 48 h), cultivated medium of cells was removed, washed cells twice with PBS and then incubated with 0.5 mg/ml MTT at 37°C. After 4-h incubation, removing the supernatant and the isopropanol was administrated to cells to dissolve formazan. The formazan concentration was detected by calculating the relative absorbance at wavelengh of 570 nm with the SpectraMax 360 pc microplate reader (Molecular Devices, LLC, Sunnyvale, CA, USA).

FACS analysis

After transfection for 24 h, cells were first fixed in the ice-cold 70% ethanol and then stained by PBS containing propidium iodide (50 µg/ml)/Annexin V and RNase A (100 µg/ml) for DNA analysis using the flow cytometry analysis on a BD FACSCalibur system (FACScan; BD Biosciences, San Diego, CA, USA). Percentage of the cells in the different phases of cellular cycle was measured using the CellQuest software version 3.3 (Becton Dickinson Immunocytometry Systems, San Jose, CA, USA).

Western blotting

Denatured cell lysates 40 µg were run on 10% gels and transferred to the polyphorylated difluoride membranes. Then, membranes were incubated with 5% BSA dissolved in TBST (Tris-buffered saline + 0.05% Tween) for 60 min and then incubated with the primary antibodies (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) in 0.5% TBS-T overnight. Primary rabbit anti-Bcl-2 antibody (dilution, 1/1,000; cat. no. ab32124), and primary rabbit anti-Bax antibody (dilution, 1/1,000; cat. no. ab32503) were all purchased from Abcam (Cambridge, MA, USA). After washing for 3 times with TBST, secondary horseradish peroxidase (HRP)-conjugated antibodies were incubated with membranes for 1 h with TBST. The secondary antibodies were detected using the ECL Plus (Amersham, Arlington Heights, IL, USA) and imaged with the GelDoc XR System (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The relative band densities were normalized to β-actin.

Statistical analysis

Statistical analysis was performed using SPSS 20.0 software (IBM, Armonk, NY, USA). Group data were expressed as mean ± standard deviation. Comparison between groups was done using one-way ANOVA test followed by post hoc test (least significant difference). Percentage (%) was used to express the enumeration data and Chi-square test was used for data analysis. P values <0.05 were considered statistically significant.

Results

miR-22 is low-expressed in the OS cells

First, we explored the miR-22 level in the OS cells (MG-63) and osteoclasts. RT-PCR results revealed that the miR-22 level in the MG-63 cells was significantly lower than that in osteoclasts (Fig. 1) (P<0.05).
Figure 1.

miR-22 was low-expressed in osteosarcoma MG-63 cells. Compared with osteoblast, the expression of miR-22 in MG-63 significantly decreased. *P<0.05.

miR-22 inhibits proliferation of the MG-63 cells

To investigate the miR-22 effects on proliferation of the MG-63 cells, miR-22 mimics were used to infect the cells. After infection for 24 h, 70% cells were successfully infected with mimics, evidenced by detected fluorescence under the fluorescence microscope (Nikon Eclipse E800; Nikon, Tokyo, Japan) (Fig. 2A). To verify the efficiency of transfection, RT-qPCR was performed. Results suggested that the level of miR-22 was nearly 8-fold of that in NC group (Fig. 2B). Next MTT assay was performed to explore cell proliferation. We found that cells infected with miR-22 mimics exhibited significant decreased cell viability at various time-points (12, 24, 48 and 72 h) (P<0.05) (Fig. 2C). These findings showed that miR-22 has inhibitory effects on MG-63 cell proliferation.
Figure 2.

miR-22 inhibits proliferation of MG-63 cells. (A) Transfection efficiency was detected by fluorescent microscopy; (B) miR-22 mimic infection induced a significant elevation of miR-22; (C) miR-22 inhibits proliferation of MG-63 cells (*compared with NC group, P<0.05). NC group, negative control group.

miR-22 promotes apoptosis of the MG-63 cells

To further study the effects of miR-22 on the MG-63 cells apoptosis. We conducted the flow cytometry experiment and found that cells infected with miR-22 mimics exhibited markedly increased apoptosis compared with blank and NC group (P<0.05) (Fig. 3). To confirm these findings, we also performed western blotting to detect levels of Bcl-2 and Bax, which were classical apoptosis-related markers. As expected, infection with miR-22 mimics remarkably elevated level of Bax and downregulated Bcl-2 (Fig. 4). These results demonstrated apoptosis-promoting effects of miR-22 in MG-63 cells.
Figure 3.

Flow cytometry was performed to detect apoptosis of MG-63 cells. Cells infected with miR-22 mimics exhibited markedly increased apoptosis compared with blank and NC group (P<0.05). NC group, negative control group.

Figure 4.

Western blot analysis was performed to detect levels of Bcl-2 and Bax. Infection with miR-22 mimics remarkably elevated level of Bax and downregulated Bcl-2 (*compared with NC group, P<0.05; #compared with blank group, P<0.05). NC group, negative control group.

miR-22 induces G0/G1 cell cycle arrest

To investigate the mechanism that miR-22 increased the MG-63 cells apoptosis, we further detected the cellular cycle of the MG-63 cells using the flow cytometry experiment among 3 groups. Results showed that percentage of cells at phase of G0/G1 in miR-22 mimic group (66.75±3.67%) were significantly higher than that in blank (52.9±2.58%) or NC group (50.5±2.45%) (P<0.05) (Fig. 5). All above results indicated that miR-22 promotes MG-63 cells apoptosis via inducing G0/G1 cell cycle arrest.
Figure 5.

miR-22 induced G0/G1 cell cycle arrest. The number of cells at G0/G1 phase in mimic group was significantly bigger than that in other groups.

Discussion

OS is a kind of primary bone cancer and is most common among children and adolescents, however its pathogenesis remains unclear and elusive due to its well-known heterogeneous character (18). Despite of the technological progresses in OS diagnosis and therapy, the mortality rate of the disease remains at a high level (5). Accumulating studies demonstrate that miRNAs play a more and more important role in regulating the apoptosis and proliferation of tumor cells (12–14). Recent researches have elucidated the miRNAs contribution in the occurrence and progression development of OS (15–17). For example, miR-27a was found to overexpress in serum of OS patients, indicating its potential to be a diagnostic marker for OS (19). Another study found that the elevated miR-130b in OS tissues was related to the aggressive progression of OS patients, thus affecting the rate of survival (20). There were also downregulated miRNAs detected in OS tumor cells, such as miR-29b, miR-181b, miR-142-5p and miR-16 (21–23) which may play a significant role in osteosarcomagenesis. miR-22 was demonstrated to be an important regulator in various tumors by much evidence. Li et al showed that miR-22 has negative effects on cell migration and invasion and was identified as a potential metastasis-inhibitor in ovarian cancer (24). Ling et al found that miR-22 exhibited dramatically the activity of anti-lung cancer in vivo and in vitro via targeting the ErbB3 (25). To our knowledge, this was the first attempt to figure out the potential mechanism that miR-22 regulates the OS cellular proliferation and apoptosis. Our present study firstly explored the miR-22 level in OS cells. Results revealed that miR-22 in MG-63 cells was significantly lower than that in osteoblasts, which was consistent with previous studies (17,26,27). Next, we found that cell proliferation was significantly inhibited by the overexpression of miR-22, indicating that miR-22 has inhibitory effects on MG-63 cells proliferation. Additionally, our results also suggested that the overexpression of miR-22 can remarkably promote cell apoptosis, suggesting that miR-22 has promotive effects on MG-63 cells apoptosis. Apoptosis-related proteins Bax also increased after infecting with miR-22 mimics. Further, we explored the potential mechanism by which miR-22 regulated the process of MG-63 cells apoptosis. As we know, cell cycle participates in cellular proliferation and apoptosis. Cell cycle arrest can induce cell apoptosis (28–30). Given this, we employed flow cytometry to explore the percentage of cells at different phases after transfected with miR-22 mimics. Results showed that overexpression of miR-22 induced a significant G0/G1 cell cycle arrest. These findings suggested that the G0/G1 cellular cycle arrest may be the potential biological mechanism of which miR-22 promotes apoptosis of MG-63 cells. There are still some limitations in our study. Our findings have not been confirmed by in vivo experiments. In addition, we did not predict the target gene for miR-22 to delineate the molecular mechanism underlying this process. In our further study, we plan to employ miR-22 lentivirus to construct stable overexpression model of miR-22 in animals for verification of our findings and also to find its target. In conclusion, our study showed that miR-22 induced G0/G1 cellular cycle arrest, thus leading to apoptosis of OS cells. These findings identified the novel tumor suppressive role of miR-22 in the development of OS. Our present study provides a new, potential therapeutic target to OS.
  30 in total

Review 1.  Biological functions of microRNAs: a review.

Authors:  Yong Huang; Xing Jia Shen; Quan Zou; Sheng Peng Wang; Shun Ming Tang; Guo Zheng Zhang
Journal:  J Physiol Biochem       Date:  2010-10-28       Impact factor: 4.158

2.  MicroRNA screening identifies circulating microRNAs as potential biomarkers for osteosarcoma.

Authors:  Hui Li; Kun Zhang; Li-Hong Liu; Yurong Ouyang; Hong-Bin Guo; Hanchong Zhang; Jie Bu; Tao Xiao
Journal:  Oncol Lett       Date:  2015-06-16       Impact factor: 2.967

3.  miR-22 inhibits osteosarcoma cell proliferation and migration by targeting HMGB1 and inhibiting HMGB1-mediated autophagy.

Authors:  Shibing Guo; Rui Bai; Wanlin Liu; Aiqing Zhao; Zhenqun Zhao; Yuxin Wang; Yong Wang; Wei Zhao; Wenxuan Wang
Journal:  Tumour Biol       Date:  2014-04-22

4.  Clinical significance of microRNA-130b in osteosarcoma and in cell growth and invasion.

Authors:  Lie-Dao Yu; Ri-Long Jin; Peng-Cheng Gu; Zhi-Heng Ling; Xiang-Jin Lin; Jing-Yu Du
Journal:  Asian Pac J Trop Med       Date:  2015-07-29       Impact factor: 1.226

Review 5.  Osteosarcoma: review of the past, impact on the future. The American experience.

Authors:  Norman Jaffe
Journal:  Cancer Treat Res       Date:  2009

6.  miRNA signatures associate with pathogenesis and progression of osteosarcoma.

Authors:  Kevin B Jones; Zaidoun Salah; Sara Del Mare; Marco Galasso; Eugenio Gaudio; Gerard J Nuovo; Francesca Lovat; Kimberly LeBlanc; Jeff Palatini; R Lor Randall; Stefano Volinia; Gary S Stein; Carlo M Croce; Jane B Lian; Rami I Aqeilan
Journal:  Cancer Res       Date:  2012-02-20       Impact factor: 12.701

7.  Osteosarcoma is characterised by reduced expression of markers of osteoclastogenesis and antigen presentation compared with normal bone.

Authors:  L Endo-Munoz; A Cumming; S Sommerville; I Dickinson; N A Saunders
Journal:  Br J Cancer       Date:  2010-06-15       Impact factor: 7.640

8.  Curcumin induces cell cycle arrest and apoptosis in human osteosarcoma (HOS) cells.

Authors:  Duk Su Lee; Mi Kyoung Lee; Jeong Hee Kim
Journal:  Anticancer Res       Date:  2009-12       Impact factor: 2.480

Review 9.  Osteosarcoma: A Meta-Analysis and Review of the Literature.

Authors:  Jill C Friebele; Jeffrey Peck; Xueliang Pan; Mahmoud Abdel-Rasoul; Joel L Mayerson
Journal:  Am J Orthop (Belle Mead NJ)       Date:  2015-12

10.  Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program.

Authors:  Lisa Mirabello; Rebecca J Troisi; Sharon A Savage
Journal:  Cancer       Date:  2009-04-01       Impact factor: 6.860

View more
  9 in total

Review 1.  miRNA signatures in childhood sarcomas and their clinical implications.

Authors:  G M Viera; K B Salomao; G R de Sousa; M Baroni; L E A Delsin; J A Pezuk; M S Brassesco
Journal:  Clin Transl Oncol       Date:  2019-04-04       Impact factor: 3.405

Review 2.  Molecular mechanism of microRNAs regulating apoptosis in osteosarcoma.

Authors:  Xueyang Cai; Wei Yin; Chao Tang; Yubao Lu; Yuqi He
Journal:  Mol Biol Rep       Date:  2022-04-26       Impact factor: 2.742

3.  Delisheng induces antiproliferation and apoptosis effects in Hep3B cells via modulation of angiogenic proteins.

Authors:  Hai-Feng Sun; Li Jing; Tao Wu; Ming Li; Ya-Huan Guo; Hui Guo; Zheng Zhao; Min-Cong Wang; Shu-Hong Wang; Ke-Jun Nan
Journal:  Oncol Lett       Date:  2017-09-26       Impact factor: 2.967

4.  Inhibition of the long non-coding RNA NEAT1 protects cardiomyocytes from hypoxia in vitro via decreased pri-miRNA processing.

Authors:  Olof Gidlöf; Kerstin Bader; Selvi Celik; Mario Grossi; Shinichi Nakagawa; Tetsuro Hirose; Bernhard Metzler; Björn Olde; David Erlinge
Journal:  Cell Death Dis       Date:  2020-08-13       Impact factor: 8.469

5.  CXCR4-mediated osteosarcoma growth and pulmonary metastasis is suppressed by MicroRNA-613.

Authors:  Yong Zhu; Lanhua Tang; Shushan Zhao; Buhua Sun; Liang Cheng; Yifu Tang; Zhongwei Luo; Zhangyuan Lin; Jianxi Zhu; Weihong Zhu; Ruibo Zhao; Bangbao Lu; Haitao Long
Journal:  Cancer Sci       Date:  2018-06-26       Impact factor: 6.716

6.  Identification of plasma microRNA-22 as a marker for the diagnosis, prognosis, and chemosensitivity prediction of osteosarcoma.

Authors:  Zhen-Bin Diao; Tian-Xiao Sun; Yi Zong; Bo-Chuan Lin; Yuan-Sheng Xia
Journal:  J Int Med Res       Date:  2020-12       Impact factor: 1.671

Review 7.  The Role of Non-Coding RNAs in Controlling Cell Cycle Related Proteins in Cancer Cells.

Authors:  Soudeh Ghafouri-Fard; Hamed Shoorei; Farhad Tondro Anamag; Mohammad Taheri
Journal:  Front Oncol       Date:  2020-11-30       Impact factor: 6.244

8.  MicroRNA-124 acts as a tumor-suppressive miRNA by inhibiting the expression of Snail2 in osteosarcoma.

Authors:  Jianghong Huang; Yujie Liang; Meiquan Xu; Jianyi Xiong; Daping Wang; Qiang Ding
Journal:  Oncol Lett       Date:  2018-02-08       Impact factor: 2.967

9.  MicroRNA‑22 regulates autophagy and apoptosis in cisplatin resistance of osteosarcoma.

Authors:  Chen-Yang Meng; Zhen-Qun Zhao; Rui Bai; Wei Zhao; Yu-Xing Wang; Liang Sun; Chao Sun; Wei Feng; Shi-Bing Guo
Journal:  Mol Med Rep       Date:  2020-08-20       Impact factor: 2.952

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.